Rafael Holdings Q1 FY2025 net loss $9.0M; Cyclo merger on track

Rafael Holdings, Inc.

2025-Q1 EPS reported -$0.37 revenue$128,000

Net loss attributable to Rafael Holdings of $9.0M ($0.37 per share) vs $3.6M loss a year ago.
Cash, cash equivalents and marketable securities of $54.3M as of October 31, 2024.
Pending merger with Cyclo Therapeutics (CYTH) expected to close in Q1 2025 after shareholder vote.
Cyclo Therapeutics' Phase 3 study for Trappsol Cyclo fully enrolled; interim results mid-2025.
R&D expenses $1.3M (up from $0.5M) on consolidation of Cornerstone and Day Three.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.